Commentary|Articles|November 19, 2026

How AI-Enabled Trial Matching Can Close the Oncology Access Gap: Q&A with Shaalan Beg, MD, MBA, FASCO, ConcertAI

In this Q&A, Shaalan Beg, MD, MBA, FASCO, chief medical officer at ConcertAI, discusses why so many patients from underrepresented groups are never asked to join a clinical trial, how AI-enabled matching and screening can make oncology access more consistent, and why the conversation with the patient must stay human.

Who gets offered a clinical trial in oncology still depends heavily on geography, site resources, and whether a busy physician happens to remember that a study is an option. Once a trial is offered, however, acceptance rates look the same across racial and ethnic groups, which points to access and screening, not patient willingness, as the real gap.

Related to this article

Closing the Community Access Gap: Q&A with Kent Thoelke, Paradigm Health
In this Q&A, Kent Thoelke, CEO of Paradigm Health, discusses why participation gaps in community and rural settings come down to both patient cost barriers and site infrastructure, how legacy workflows weigh on community clinics, and what policy and technology changes it would take to make clinical research a real care option for more patients.
© putilov_denis - © putilov_denis - stock.adobe.com
Sponsors rigorously vet CROs for oncology expertise but rarely apply the same scrutiny to the IRB reviewing their trials, even though increasingly complex protocols require reviewers with substantive therapeutic knowledge, not just a rostered oncologist.